Kailera raises $625M in record obesity biotech IPO
The offering priced above the $528.5 million the company had outlined days earlier, funding a portfolio of in-licensed Chinese obesity candidates.
TR
By Tom Reyes · Markets Editor
Apr 17 03:00 ETSource: Fierce Biotech
The wire
- 01Kailera Therapeutics completed a $625 million IPO, which Fierce Biotech describes as record-breaking for an obesity biotech; the CEO said the company knew it was in a good spot beforehand.
- 02Large obesity financings signal continued investor appetite for incretin competitors beyond Lilly and Novo, which shapes future supply and pricing in the class.
- 03Kailera's assets are in-licensed from China and still need to produce late-stage Western data; no approved product backs the valuation yet.
From the source
Read at fiercebiotech.comKailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO